About P2P

P2P will be utilizing the established participant population from the PPMI study to provide the infrastructure for this perpetual multi-center, multi-regimen proof of concept phase 2A randomized platform trial. The goal for this trial will be to evaluate the safety and early efficacy of investigational products for the treatment of Early-Stage Neuronal Alpha-Synuclein Disease (NSD) populations. Early stage NSD includes participants with alpha-synuclein pathology, presence of dopamine dysfunction, motor, and non-motor clinical manifestations but lack of related functional impairment.